Novo Nordisk Partners with Vivani Medical to Improve Obesity Drug Adherence with Biannual Implant
The obesity drug market, generating between $30 billion and $60 billion in 2025 for pharmaceutical giants Eli Lilly and Novo Nordisk, faces a significant challenge with high patient dropout rates. A recent study presented at the Endo conference, analyzing data from 60,000 patients between 2019 and 2025, found that about 40% of patients discontinue obesity medications within one year, and 60% within two years. However, many patients resume treatment after a break, indicating demand despite adherence barriers such as injection aversion and complex dosing protocols.
Novo Nordisk has entered a collaboration with Israeli company Vivani Medical to develop a drug implant that administers obesity medications Wegovy and Ozempic twice a year. This implant aims to reduce treatment discontinuation by providing a steady drug release, minimizing side effects fluctuations, and easing the burden of frequent injections and prescription management. Although early-stage, the implant could become a viable option for long-term weight maintenance, with the possibility of immediate removal if adverse effects occur.
Separately, the Israeli Association of Plastic and Aesthetic Surgeons reported a surprising cosmetic side effect among GLP-1 drug users: significant fat loss in the earlobes, dubbed "Ozempic ears." This rapid fat reduction can cause earlobes to appear thinner and less able to support heavy earrings. Some patients also report hearing issues and balance problems, likely due to the fast fat loss in the ear area. Treatments include hyaluronic acid injections to restore volume, and managing the rate of fat loss may help mitigate symptoms.
The rise in obesity drug use has also boosted demand for plastic surgery procedures such as facelifts and body contouring, with a 280% increase in consultations reported by the Israeli surgeons' association.
In related biotech news, Israeli company Omnix Medical will lead a European consortium funded with 8 million euros to develop a new antibiotic targeting drug-resistant infections, including the critical pathogen Acinetobacter baumannii. Omnix’s drug, based on research from the Hebrew University, is in Phase II clinical trials and has previously received grants from the US NIH and Israeli Innovation Authority. Founded in 2015, Omnix has raised $43 million to date and aims to advance to Phase III trials soon.
